Nuformix plc (LON:NFX – Get Free Report)’s stock price rose 10.6% during trading on Tuesday . The stock traded as high as GBX 0.09 ($0.00) and last traded at GBX 0.09 ($0.00). Approximately 14,352,294 shares traded hands during mid-day trading, a decline of 79% from the average daily volume of 69,985,758 shares. The stock had previously closed at GBX 0.09 ($0.00).
Nuformix Price Performance
The firm has a market cap of £1.16 million, a PE ratio of -2.86 and a beta of 1.22. The business has a 50-day simple moving average of GBX 0.07 and a 200 day simple moving average of GBX 0.08.
Nuformix (LON:NFX – Get Free Report) last issued its earnings results on Wednesday, January 29th. The company reported GBX (0.46) (($0.01)) earnings per share (EPS) for the quarter.
Nuformix Company Profile
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis.
See Also
- Five stocks we like better than Nuformix
- What Is WallStreetBets and What Stocks Are They Targeting?
- Confluent: How Data Streaming May Transform AI
- How to Calculate Return on Investment (ROI)
- The Behemoth BlackRock’s Next Trillion Comes From Private Assets
- Top Biotech Stocks: Exploring Innovation Opportunities
- Rivian’s Rough Patch: Is the Dip a Doorway to Long-Term Gains?
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
